NASDAQ: NVAXNovavax Inc Stock
$3.89+0.00 (+0%)
Updated Apr 18, 2024
NVAX Price
$3.89
Fair Value Price
N/A
Market Cap
$544.42M
52 Week Low
$3.53
52 Week High
$11.36
P/E
-0.72x
P/B
-0.76x
P/S
0.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$983.71M
Earnings
-$545.06M
Gross Margin
65.1%
Operating Margin
-53.74%
Profit Margin
-55.4%
Debt to Equity
-3.51
Operating Cash Flow
-$714M
Beta
1.14
Next Earnings
May 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NVAX Overview
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NVAX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVAX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NVAX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
NVAX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more NVAX due diligence checks available for Premium users.
Be the first to know about important NVAX news, forecast changes, insider trades & much more!
NVAX News
Valuation
NVAX fair value
Fair Value of NVAX stock based on Discounted Cash Flow (DCF)
Price
$3.89
Fair Value
$11.30
Undervalued by
65.59%
NVAX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NVAX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.72x
Industry
15.68x
Market
41.33x
NVAX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.76x
Industry
5.76x
NVAX's financial health
Profit margin
Revenue
$291.3M
Net Income
-$178.4M
Profit Margin
-61.2%
NVAX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NVAX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.8B
Liabilities
$2.5B
Debt to equity
-3.51
NVAX's short-term liabilities ($1.64B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVAX's short-term assets ($1.14B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVAX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NVAX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$176.8M
Investing
-$9.1M
Financing
$100.4M
NVAX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NVAX vs Biotech Stocks
Novavax Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.